Study will examine prior authorization and other access restrictions at 15 of the largest US commercial payers for a group of 27 drugs.

Study will look at prior authorization, step therapy and required medication switching for drugs considered to be reasonably priced.

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Arix Biosciences has unveiled three significant changes to the organization, including the appointment of Christian Schetter as co-managing director, which the healthcare-focused venture capitalist hopes will keep its impressive record of biotech investments on track.